Back to Directory

Dextromethorphan (Cough Suppressant)

DXM, Robitussin, Delsym

Visual ViewRaw DataInteraction Data

Meta Information

ID:dextromethorphan
Name:Dextromethorphan (Cough Suppressant)
Schema Version:1.5

Alternate Names

  • DXM
  • Robitussin
  • Delsym

Active Compound

dextromethorphan

Intervention Type

therapeutic_agent

Delivery

Route:
oral
Scope:
  • systemic

Regulatory Status

  • us:otc_drug
  • us:rx_drug

Indication

Focus:
symptom_management
Description:
Temporary relief of cough caused by minor throat and bronchial irritation.

Typical Protocol

  • For cough suppression, 10-20 mg every 4 hours or 30 mg every 6-8 hours as needed.
  • Extended-release formulations are typically dosed at 60 mg every 12 hours.

Expected Cost Mean

Low Cost:
5
High Cost:
20
Cost Type:
monthly
Description:
Generic over-the-counter cough syrup; not typically covered by insurance.

Summary

Dextromethorphan suppresses the cough reflex by acting on the brain's cough center in the medulla oblongata. It also functions as a sigma-1 receptor agonist and NMDA receptor antagonist, mechanisms being explored for potential neuroprotective and antidepressant effects, though its relevance to general healthspan is currently speculative and unproven in humans.

Purpose

An over-the-counter drug for suppressing cough with speculative neuroprotective properties.

Card Summary

An over-the-counter cough suppressant with speculative neuroprotective properties via sigma-1 receptor agonism.

Drug Class

morphinan_antitussive

Drugs In Class

Empty Array

Impact

Score:
2
Justification:
No direct human evidence for healthspan benefits; based on speculative preclinical mechanisms.

Evidence

Grade:
C
Score:
2.5
Justification:
Evidence is limited to preclinical models exploring its secondary pharmacological targets.

Safety

Score:
4.5
Justification:
Generally safe at OTC doses but has abuse potential and risk of serotonin syndrome.

Flags

  • High potential for abuse at supratherapeutic doses, causing dissociative and hallucinogenic effects.
  • Risk of life-threatening serotonin syndrome when combined with MAOIs, SSRIs, or SNRIs.
  • Metabolism is highly variable due to CYP2D6 genetic polymorphisms, affecting efficacy and safety.
  • Common side effects include dizziness, drowsiness, nausea, and confusion.

Verdict

An unproven healthspan agent; use only for its intended purpose (cough).

Created

2026-04-30T01:27:58.297902Z

Ai Model

Gemini 2.5 Pro (High)

Non Healthspan

True